Table 4.
Case series and retrospective and prospective studies of AIs in the setting of recurrent, metastatic or unresectable uLMS
| Study (y) | n | Age | ER/PR | Treatment for recurrence or metastasis | Response | Duration (mo) | Prognosis |
|---|---|---|---|---|---|---|---|
| Ioffe (2009)49 | 4 | – |
1 +/+ 3 ± |
1 Anastrozole 3 Letrozole |
3 SD,1 PR | 30‐50 | – |
| Thanopoulou (2014)40 | 16 | 39‐72 | 16 +/+ |
13 Letrozole (2.5 mg/d) 2 Letrozole (2.5 mg/d) + Goserelin 1 Letrozole(2.5 mg/d) → Anastrozole(1 mg/d) |
2 PR, 8 SD, 6 PD | 13 | Median PFS: 14 mo |
| First‐line therapy | 20 | 17 +/+ |
3 PR, 11 SD, 6 PD Effective rate: 70% |
||||
| Altman (2012)13 | 3 | 44‐48 |
1 +/+ 2 ± |
2 Anastrozole (1 mg/d) 1 Anastrozole (1 mg/d) → Letrozole (2.5 mg/d) |
2 SD, 1 PD | 4.2 (mean) | Mean OS: 44.3 mo |
| Thanopoulou (2014)40 | 6 | 40‐74 | 6 +/+ |
5 Exemestane (25 mg/d) 1 Anastrozole (1 mg/d) |
3 SD, 3 PD | 3 | 1‐y PFS rate: 80% |
| George (2014)43 | 27 | 44‐74 | 22 +/+, 4 ± | Letrozole (2.5 mg/d) | 14 SD, 13 PD | 0.4‐9.9 | 12‐week PFS rate: 50% |
| Second‐line therapy | 36 | 29 +/+ |
19 SD, 17 PD Effective rate: 52.7% |
||||
| O'Cearbhaill (2010)a 66 | 34 | 35‐74 |
23 +/+, 5 ‐/‐, 3 ‐/? |
Letrozole Exemestane Anastrozole |
3PR, 11SD, 20PD | 1‐84 | Median PFS: 2.9 mo |
| Total | 90 | 69 +/+ |
6 PR, 41 SD, 43 PD Effective rate: 52.2% |
Effective rate: CR+PR+SD.
CR, complete response; OS, overall survival; PD, progression of disease; PFS, progression free survival; PR, partial response; SD, stable disease; —, The data were not described clearly; →, It means a change from the former one to the latter one.
a
This study did not mention whether AIs were used as first‐line therapy or as second‐line therapy.